About Xlumena
Xlumena is a Healthcare company based in Mountain View (United States) founded in 2008, and was acquired by Boston Scientific in April 2015. Image-guided therapeutic endoscopy devices are developed for medical procedures. Xlumena has raised $73.68 million across 7 funding rounds from investors including Boston Scientific, Western Technology Investment and Ascent Biomedical Ventures. The company has 2 employees. Its focus areas include Life Sciences, Gastroenterology, Medical Devices and Therapeutic Devices. Its competitors include Salient Surgical Technologies, CalmiGo and Autem Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system; Translumenal Access for Translumenal delivery of endoscopic instruments and devices using the integrated Exchange Free (XF) delivery system; Gallbladder Drainage that drains the gallbladder into the duodenum or stomach using a lumenal approximating stent and precision delivery system; and Bile and Pancreatic Duct Drainage, which creates an anastomotic bypass to drain the bile ducts or pancreatic ducts into the duodenum using the integrated XF delivery system, lumenal approximation tools, and novel anchor stent. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen.
- Headquarters Mountain View, United States
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website xlumena.com
- Social X
- Acquired by Boston Scientific (Apr 2015)
- Legal Name Xlumena
- Total Equity Funding$73.68M (USD)
in 7 rounds
- Latest Funding Round$25M (USD), Series C
Dec 2014
- InvestorsBoston Scientific
& 7 more
- Employee Count2
- Acquired byBoston Scientific
(Apr 2015)
Funding Insights of Xlumena
Xlumena has successfully raised a total of $73.68M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73.68M
- Total Rounds 7
- Last Round Series C — $25M
- First Round $6.15M
(May 2008)
- Investors Count 7
All 7 funding rounds of Xlumena with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $25M | Series C | – | Third Point | |
| Feb 2014 | $20.6M | Series C | – | – | – |
| Oct 2013 | $6M | Series B | – | – | – |
| Aug 2012 | $5.92M | Series B | – | – | – |
| Apr 2011 | $7M | Series B | – | Aperture Venture Partners, Western Technology Investment | – |
| May 2010 | $3M | Series A | – | – | – |
| May 2008 | $6.15M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in Xlumena
Xlumena has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Western Technology Investment and Ascent Biomedical Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| abvlp.com | ||||
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
VC firm investing in the US | prismventure.com | Westwood, United States | ||
| clsvc.com | ||||
Venture debt is provided globally across multiple sectors. | 1980 | westerntech.com | Portola Valley, United States | |
| charterls.com | ||||
Third Point is engaged in opportunistic investing across various strategies. | 1995 | thirdpoint.com | New York, United States | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Xlumena
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xlumena
4 dated milestones of Xlumena across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Xlumena is founded.
- Funding First funding round of $6.1M.
- Funding Latest funding round, Series C, of $25.0M.
- Exit Acquired by Boston Scientific.
Competitors of Xlumena
Xlumena has 3 listed competitors in our database, 2 of them funded. They include Salient Surgical Technologies, CalmiGo and Autem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| salientsurgical.com | 1999 | Portsmouth, United States | $120.5M | Electrosurgical systems for surgical resections and procedures are developed. | ||
| calmigo.com | 2010 | New York, United States | Stress-relief devices are developed using smart breathing regulation technology. | |||
| autemtherapeutics.com | 2022 | Hanover, United States | $11.5M | 10 | Bioelectric platforms for cancer treatment are developed. |
Detailed competitors of Xlumena
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Xlumena (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xlumena
Xlumena was founded in 2008.
Xlumena is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Xlumena is a funded company, having raised a total of $73.68M across 7 funding rounds to date. The company's 1st funding round was a Series A of $6.15M, raised on May 2008.
Xlumena has 2 employees.
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system; Translumenal Access for Translumenal delivery of endoscopic instruments and devices using the integrated Exchange Free (XF) delivery system; Gallbladder Drainage that drains the gallbladder into the duodenum or stomach using a lumenal approximating stent and precision delivery system; and Bile and Pancreatic Duct Drainage, which creates an anastomotic bypass to drain the bile ducts or pancreatic ducts into the duodenum using the integrated XF delivery system, lumenal approximation tools, and novel anchor stent. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen.
Xlumena's top competitors include CalmiGo, Salient Surgical Technologies and Autem Therapeutics.
Xlumena has 8 investors. Key investors include Boston Scientific, Western Technology Investment, Ascent Biomedical Ventures, Aperture Venture Partners, and Prism Venture Partners.
Xlumena operates through Xlumena.
Yes. Xlumena was acquired by Boston Scientific in April 2015.